Initiator Pharma A/S (INIT.ST) Research
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.
Market snapshot
- Symbol
- INIT.ST
- Price
- $2.79
- Day change
- -2.79%
- Market cap
- $129.8M
- P/E ratio
- -5.71x
- 52-week range
- 2.53-4.17
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
- Alzinova AB (publ) (ALZ.ST)
- Annexin Pharmaceuticals AB (publ) (ANNX.ST)
- Bio-Works Technologies AB (publ) (BIOWKS.ST)
- Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
- IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
- Isofol Medical AB (publ) (ISOFOL.ST)
- iZafe Group AB (publ) (IZAFE-B.ST)
- Karolinska Development AB (publ) (KDEV.ST)
Open Initiator Pharma A/S (INIT.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.